Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.055 +0.035 (+1.73%)

Streaming Delayed Price Updated: 12:09 PM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate ↗

September 29, 2021

Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber...

Via Benzinga

Why Shares of Editas Medicine Are Lower This Morning ↗

September 29, 2021

Incomplete data is disappointing investors after a long wait.

Via The Motley Fool

Editas Medicine Stock Plunges As CRISPR Gene-Editing Drug Fails To Impress ↗

September 29, 2021

Editas is working on a treatment for a blindness-causing genetic disorder.

Via Investor's Business Daily

Biotech Playbook Revisited As Technicals Weaken ↗

September 27, 2021

Recent breakthroughs with mRNA vaccines over the past two years have shown the enormous potential for transformative therapies. DNA sequencing took off five years ago and new applications are still...

Via Talk Markets

'Fast Money Halftime Report' Picks For September 13 ↗

September 13, 2021

On CNBC's "Fast Money Halftime Report," Shannon Saccocia said Stryker Corporation (NYSE: SYK) has had a really nice run since last year. She sees more upside...

Via Benzinga

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

10 Biggest Price Target Changes For Friday ↗

September 10, 2021

Wells Fargo lowered the price target on General Motors Company (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021 ↗

September 24, 2021

Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ:

Via Benzinga

3 Red-Hot Healthcare Stocks to Buy in September ↗

September 09, 2021

These businesses are firing on all cylinders.

Via The Motley Fool

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming ↗

September 03, 2021

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021 ↗

September 10, 2021

Upgrades According to JonesTrading, the prior rating for Orchid Island Capital Inc (NYSE:

Via Benzinga

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today ↗

August 23, 2021

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.

Via InvestorPlace

60 Biggest Movers From Yesterday ↗

August 24, 2021

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pfizer for $18.50 per share,...

Via Benzinga

35 Stocks Moving In Monday's Mid-Day Session ↗

August 23, 2021

Gainers Trillium Therapeutics Inc. (NASDAQ: TRIL) shares climbed 187.8% to $17.53 after the company agreed to be acquired by Pfizer for $18.50 per share, implying an equity value...

Via Benzinga

25 Stocks Moving in Monday's Pre-Market Session ↗

August 23, 2021

Gainers Greenpro Capital Corp. (NASDAQ: GRNQ) rose 48.7% to $1.13 in pre-market trading. Greenpro Capital shares gained 16% on Friday after the company announced its Angkasa-X...

Via Benzinga

Editas Medicine Unveils Preclinical Data From New Gene Editing Technology ↗

August 23, 2021

Editas Medicine Inc (NASDAQ: EDIT) announced data on a new gene-editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in). Data were...

Via Benzinga

Will Moderna Buy Editas Medicine to Jump Into Gene Editing? ↗

August 12, 2021

Editas could be an attractive acquisition candidate for the big vaccine maker.

Via The Motley Fool

Why Editas Medicine Beat the Market on Monday ↗

August 09, 2021

Another analyst ups his recommendation on the stock.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021 ↗

August 09, 2021

Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ:

Via Benzinga

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today ↗

August 05, 2021

Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021 ↗

August 05, 2021

Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ:

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

August 05, 2021

Keybanc boosted the price target for HubSpot, Inc. (NYSE:

Via Benzinga

Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript ↗

August 04, 2021

EDIT earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Editas Medicine Stock Shows Improved Relative Strength Rating ↗

July 22, 2021

A Relative Strength Rating upgrade for Editas Medicine shows improving technical performance. Will it continue?

Via Investor's Business Daily

Editas Stock Isn’t Worth Buying This Early Into Treatment Development ↗

July 21, 2021

EDIT stock is part of a pioneering movement in CRISPR gene editing, but there's no way to know whether the company will succeed long term.

Via InvestorPlace

Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week ↗

July 16, 2021

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Via The Motley Fool

After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding ↗

July 15, 2021

It's a good time to be a gene-editing company.

Via The Motley Fool

WHO Issues Framework For Governance For Gene Editing Technologies ↗

July 12, 2021

A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or...

Via Benzinga

A Comprehensive Guide To Genomic ETFs ↗

July 11, 2021

Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon...

Via Talk Markets

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.